Drug Target Review

JULY 12, 2023

Molecular-level biochemical assays like transcriptomics, genomics and proteomics have emerged as valuable tools for identifying potential targets in cancer treatment through deep cyclic inhibition (DCI).

Biochemical Assays 98

Biochemical Assays Treatment Bioinformatics Disease 98

Drug Target Review

JANUARY 10, 2024

Both are a focus for exciting new small-molecule drug therapeutics that target cancers and autoimmune disorders. The Transcreener HTS Assay platform accelerates these efforts by providing robust and easy-to-use biochemical assays for key enzymes in the pathways.

DNA 104

DNA Biochemical Assays Small Molecule Drugs 104

Covalent Modifiers

JULY 25, 2024

We have integrated structural and quantitative proteomics with biochemical assays to decipher the mode of action of covalent USP30 inhibition by a small molecule containing a cyanopyrrolidine reactive group, USP30-I-1. The inhibitor demonstrated high potency and selectivity for endogenous USP30 in neuroblastoma cells.

Biochemical Assays 65

Biochemical Assays Small Molecule Treatment Disease 65

Covalent Modifiers

MARCH 17, 2023

These dual-covalent small molecules reversibly react with a nucleophilic amino acid on each of the partner proteins to dynamically crosslink the protein complex. Based on a focused library of dual-reactive small molecules, a molecular glue tool compound was rapidly developed.

Biochemical Assays 52

Biochemical Assays Small Molecule Drugs 52

Drug Discovery World

SEPTEMBER 29, 2022

The company has narrowed down their decision to three options: Option #1: Company Z performs the project internally and screens their in-house collection of 250,000 small molecules using a traditional fluorescence-based biochemical assay. protein-protein or small molecule-target interactions). 2: [link].

Small Molecule 130

Small Molecule Assay Development DNA Biochemical Assays 130

Drug Target Review

NOVEMBER 1, 2023

The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials. We often screen using a biochemical assay, but we can conduct cell-based screening as well. We need to build the assays that we need for compound screening.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

ASPET

DECEMBER 21, 2023

Based on the druggability of DR3penA, we sought to investigate its effects on respirable particulate silicon dioxide (SiO 2 )- and soluble chemical paraquat (PQ)-induced pulmonary fibrosis in this study by using western blot, RT-qPCR, immunofluorescence, H&E and Masson staining, immunohistochemistry and serum biochemical assays.

Biochemical Assays 40

Biochemical Assays Small Molecule Regulations Disease 40